fda approved glp-1 drugs Overview of structure, date of approval and dosage frequency of Compound versions of GLP-1 drugs

Records were reviewed for patient characteristics and medication type and doses

Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist

The single-dose segment held the largest share, owing primarily to its ease of administration and convenience for patients

The clinical results so far are hard to ignore

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk